Key facts
- It has raised $32.5M; the latest was Later Stage VC ($11.0M) in Oct 2024.
- Notable investors include Innovation Authority, Consensus Business Group, Agroline (agricultural equipment), Cogentix Medical, Israel Biotech Fund — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Vensica
- ·The full record, as it builds
Funding rounds
No funding rounds for Vensica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vensica
Developer of an ultrasound-based drug delivery system designed to treat an overactive bladder. The company's system leverages the known properties of ultrasound and is needle-free, and the drug will be instilled in a quick, pain-free procedure after the delivery of ultrasound to the urinary bladder to improve the treatment and reduce recurrence rates, enabling medical professionals to safely and effectively deliver therapy to patients suffering from urinary overactive bladder.
- Sector
- Healthcare
- HQ
- Netanya, Israel
- Founded
- 2014
- Employees
- 10
- Website
- vensica.com/
- Ownership
- Privately Held (backing)
Vensica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vensica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vensica in its N-PORT filings yet. We sweep new filings monthly.